prasterone
Commercial- Indications
- Vulvovaginal atrophy
Company intelligence / Profile preview
Endoceutics
Quebec City, Quebec, Canadaendoceutics.com ↗
- Ownership
- Private
- Employees
- ~26
- Development stage
- Commercial
01
Overview
Endoceutics developed Intrarosa® (prasterone vaginal ovules), approved by the US FDA in November 2016 for moderate to severe dyspareunia due to vulvovaginal atrophy in postmenopausal women. The company has additional late-stage clinical programs targeting menopausal symptoms, osteoporosis, breast cancer, prostate cancer, endometriosis, and male hypogonadism. Its main commercial asset is Intrarosa; other pipeline assets are preclinical or discontinued[1][4].
- Therapeutic areas
- Women's HealthOncologyEndocrinology
- Modalities
- Small moleculeHormone
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Lupin Pharma Canada—commercialization partner for Intrarosa® in CanadaOther global commercialization partners not specified.
Beyond the preview
Go deeper on Endoceutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Endoceutics.